These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21092676)

  • 21. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
    Zhao X; Li J; Zhuo J; Cai L
    Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas.
    Kouvaraki MA; Liakou C; Paraschi A; Dimas K; Patsouris E; Tseleni-Balafouta S; Rassidakis GZ; Moraitis D
    Surgery; 2011 Dec; 150(6):1258-65. PubMed ID: 22136849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M; Rowinsky EK
    Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.
    Wang YD; Su YJ; Li JY; Yao XC; Liang GJ
    Int J Clin Exp Pathol; 2015; 8(5):5182-8. PubMed ID: 26191215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
    Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammalian target of rapamycin regulates expression of β-catenin in hepatocellular carcinoma.
    Feng Z; Fan X; Jiao Y; Ban K
    Hum Pathol; 2011 May; 42(5):659-68. PubMed ID: 21239045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC; Schaefer E; Christensen JG; Salgia R
    Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
    Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
    Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
    Ji J; Zheng PS
    Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of mTOR inhibitor rapamycin on Smad 3 protein and collagen type I expression in rat myocardial fibroblasts infected with coxsackie virus B 3].
    Chen CY; Sun YN; Yang ZC; Cai ZL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):156-60. PubMed ID: 19099956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methoxychalcone induces cell-cycle arrest and apoptosis in human hormone-resistant prostate cancer cells through PI 3-kinase-independent inhibition of mTOR pathways.
    Sun YW; Huang WJ; Hsiao CJ; Chen YC; Lu PH; Guh JH
    Prostate; 2010 Sep; 70(12):1295-306. PubMed ID: 20623631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
    Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapamycin inhibits tumor growth of human osteosarcomas.
    Zhao S; Lu N; Chai Y; Yu X
    J BUON; 2015; 20(2):588-94. PubMed ID: 26011354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of rapamycin-induced cell death.
    Galluzzi L; Morselli E; Kepp O; Vitale I; Younes AB; Maiuri MC; Kroemer G
    Methods Mol Biol; 2012; 821():125-69. PubMed ID: 22125064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin inhibits proliferation and induces autophagy in human neuroblastoma cells.
    Lin X; Han L; Weng J; Wang K; Chen T
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30393233
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells].
    Zhou LH; Zhu XP; Xiao HF; Xin PL; Li CT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1397-1405. PubMed ID: 29070114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.